Literature DB >> 25596129

Oncogenic TPM3-ALK activation requires dimerization through the coiled-coil structure of TPM3.

Yosuke Amano1, Rie Ishikawa1, Toshio Sakatani1, Junji Ichinose2, Mitsuhiro Sunohara1, Kousuke Watanabe1, Hidenori Kage1, Jun Nakajima2, Takahide Nagase1, Nobuya Ohishi1, Daiya Takai3.   

Abstract

Inflammatory myofibroblastic tumor (IMT) is a mesenchymal tumor that can arise from anywhere in the body. Anaplastic lymphoma kinase (ALK) gene rearrangements, most often resulting in the tropomyosin 3 (TPM3)-ALK fusion gene, are the main causes of IMT. However, the mechanism of malignant transformation in IMT has yet to be elucidated. The purpose of this study was to clarify the role of the TPM3 region in the transformation of IMT via TPM3-ALK. Lentivirus vectors containing a TPM3-ALK fusion gene lacking various lengths of TPM3 were constructed and expressed in HEK293T and NIH3T3 cell lines. Focus formation assay revealed loss of contact inhibition in NIH3T3 cells transfected with full-length TPM3-ALK, but not with ALK alone. Blue-native polyacrylamide gel electrophoresis (BN-PAGE) revealed that TPM3-ALK dimerization increased in proportion to the length of TPM3. Western blot showed phosphorylation of ALK, ERK1/2, and STAT3 in HEK293T cells transfected with TPM3-ALK. Thus, the coiled-coil structure of TPM3 contributes to the transforming ability of the TPM3-ALK fusion protein, and longer TPM3 region leads to higher dimer formation.
Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Blue-native polyacrylamide gel electrophoresis; Coiled-coil structure; Inflammatory myofibroblastic tumor; TPM3-ALK

Mesh:

Substances:

Year:  2015        PMID: 25596129     DOI: 10.1016/j.bbrc.2015.01.014

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

Review 1.  ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma.

Authors:  Chien-Feng Li; Hsuan-Ying Huang; Mei-Jun Zhu; Jen-Chieh Lee; Adrián Mariño-Enríquez; Chung-Ta Lee; Wen-Bin Ou; Jason L Hornick; Jonathan A Fletcher
Journal:  J Pathol       Date:  2016-12-15       Impact factor: 7.996

2.  Novel TENM3-ALK fusion is an alternate mechanism for ALK activation in neuroblastoma.

Authors:  Mitsuteru Hiwatari; Masafumi Seki; Ryosuke Matsuno; Kenichi Yoshida; Takeshi Nagasawa; Aiko Sato-Otsubo; Shohei Yamamoto; Motohiro Kato; Kentaro Watanabe; Masahiro Sekiguchi; Satoru Miyano; Seishi Ogawa; Junko Takita
Journal:  Oncogene       Date:  2022-04-11       Impact factor: 9.867

3.  ALK Fusion Partners Impact Response to ALK Inhibition: Differential Effects on Sensitivity, Cellular Phenotypes, and Biochemical Properties.

Authors:  Merrida A Childress; Stephen M Himmelberg; Huiqin Chen; Wanleng Deng; Michael A Davies; Christine M Lovly
Journal:  Mol Cancer Res       Date:  2018-07-12       Impact factor: 5.852

4.  Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers.

Authors:  Noriko Hirai; Takaaki Sasaki; Shunsuke Okumura; Yoshinori Minami; Shinichi Chiba; Yoshinobu Ohsaki
Journal:  Front Oncol       Date:  2020-04-02       Impact factor: 6.244

5.  The prognostic value of TPM1-4 in hepatocellular carcinoma.

Authors:  Zhihui Tian; Jian Zhao; Yusheng Wang
Journal:  Cancer Med       Date:  2021-11-30       Impact factor: 4.452

6.  Lung adenocarcinoma with an uncommon CCDC85A-ALK fusion responding to alectinib: A case report.

Authors:  Jieheng Lin; Wenping Wang; Jietao Lin; Ruilian Chen; Yang Cao
Journal:  J Cell Mol Med       Date:  2022-09-14       Impact factor: 5.295

Review 7.  ALK-TPM3 rearrangement in adult renal cell carcinoma: a case report and literature review.

Authors:  Jing Yang; Lei Dong; Hong Du; Xiu-Bo Li; Yan-Xiao Liang; Guo-Rong Liu
Journal:  Diagn Pathol       Date:  2019-10-18       Impact factor: 2.644

8.  Nicotine promotes the development of oral leukoplakia via regulating peroxiredoxin 1 and its binding proteins.

Authors:  Moci Qi; Lingyu Li; Xiaofei Tang; Yunping Lu; Min Wang; Jing Yang; Min Zhang
Journal:  Braz J Med Biol Res       Date:  2021-05-31       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.